Procarbazine Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 50 mg
Reference Brands: Matulane(US), Procarbazine(EU)
Category:
Oncology Cancer Care
Procarbazine Capsules 50 mg are used in the treatment of Hodgkin lymphoma, non-Hodgkin lymphoma, and certain brain tumors. As an alkylating chemotherapy agent, Procarbazine interferes with DNA replication, preventing cancer cell growth. Approved in both the U.S. and EU, it is a key part of combination chemotherapy regimens for oncology B2B distribution.
Procarbazine is available in Capsules
and strengths such as 50 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Procarbazine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Procarbazine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Procarbazine Capsules 50 mg are an essential oral chemotherapy drug used in the treatment of Hodgkin lymphoma, non-Hodgkin lymphoma, and certain brain tumors. As an alkylating agent, it interferes with DNA replication, preventing cancer cell growth. Approved in both the U.S. and EU, Procarbazine is typically used in combination with other chemotherapy agents. Available in 50 mg capsules, it plays a crucial role in oncology B2B distribution, supporting hospitals and oncology centers in treating hematologic and solid tumors. Its use in combination therapies provides a comprehensive approach to cancer treatment.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing